Dr Thomas Bogenrieder
Chief Clinical Officer
Thomas joined AMAL Therapeutics in 2020 as Chief Clinical Officer.
Thomas has more than 25 years of experience in academic research (molecular biology and immunology), clinical practice (dermatology, clinical immunology and immune-oncology) and clinical development in the biopharmaceutical industry. He has worked in the biopharmaceutical industry for almost 15 years, holding positions in oncology drug development and medical affairs, encompassing assignments in Germany, Europe and at a global level.
Thomas qualified in Medicine at the Albert-Ludwigs-University, Freiburg (Germany), after studying medicine in Homburg/Saar (Germany) and at Louis Pasteur University Strasbourg (France). He completed a post-doctoral fellowship in molecular cancer biology at Memorial Sloan-Kettering Cancer Center in New York and worked as a visiting scientist at the Wistar Institute in Philadelphia. Thomas also holds a PhD in “Clinicopathological and Molecular Aspects of Cutaneous Melanoma” from the University of Utrecht (The Netherlands). He is board-certified and practiced Dermatology and Clinical Immunology at the University of Regensburg and in private practice in Germany before entering the Industry.